• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Research Briefing on 2-Chloro-4-sulfamoylbenzoic Acid (CAS: 53250-84-3): Recent Advances and Applications

2-Chloro-4-sulfamoylbenzoic Acid (CAS: 53250-84-3) is a key intermediate in the synthesis of various pharmacologically active compounds, particularly in the development of diuretics and carbonic anhydrase inhibitors. Recent studies have highlighted its significance in medicinal chemistry, owing to its structural versatility and biological activity. This briefing provides an overview of the latest research findings, focusing on synthetic methodologies, biological applications, and potential therapeutic uses.

A 2023 study published in the Journal of Medicinal Chemistry explored the optimization of synthetic routes for 2-Chloro-4-sulfamoylbenzoic Acid, emphasizing green chemistry principles. Researchers achieved a 15% increase in yield by employing microwave-assisted synthesis, reducing reaction times and minimizing waste. This advancement is particularly relevant for industrial-scale production, where efficiency and sustainability are critical considerations.

In the realm of drug discovery, 2-Chloro-4-sulfamoylbenzoic Acid has been investigated as a scaffold for novel carbonic anhydrase inhibitors. A recent Bioorganic & Medicinal Chemistry Letters article (2024) demonstrated its efficacy in inhibiting tumor-associated carbonic anhydrase isoforms, suggesting potential applications in oncology. The study reported IC50 values in the nanomolar range, underscoring its potency as a lead compound for anticancer drug development.

Further research has explored the compound's role in designing next-generation diuretics. A 2024 preclinical study utilized computational modeling to predict the binding affinity of 2-Chloro-4-sulfamoylbenzoic Acid derivatives with renal carbonic anhydrase. The results indicated enhanced selectivity compared to traditional diuretics, potentially reducing off-target effects. These findings were validated through in vitro assays, confirming the compound's promise as a template for safer diuretic agents.

Recent advancements in analytical techniques have also facilitated the characterization of 2-Chloro-4-sulfamoylbenzoic Acid and its metabolites. A 2023 publication in Analytical and Bioanalytical Chemistry detailed a novel LC-MS/MS method for quantifying the compound in biological matrices, achieving a detection limit of 0.1 ng/mL. This method is expected to support pharmacokinetic studies and accelerate the compound's transition into clinical trials.

In conclusion, 2-Chloro-4-sulfamoylbenzoic Acid (CAS: 53250-84-3) continues to be a molecule of significant interest in pharmaceutical research. Its dual role as a synthetic intermediate and bioactive compound positions it as a valuable asset in drug discovery pipelines. Future research directions may focus on expanding its therapeutic applications and optimizing its physicochemical properties for enhanced bioavailability.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)